BioMarin (BMRN) Stock Secures Victory in Patent Dispute, Gains Royalty Stream Through 2030
BioMarin (BMRN) and Ascendis Pharma settled a global patent dispute over Yuviwel, with BioMarin receiving 20% royalties on U.S. sales and 18% on sales in the EU, Brazil, and South Korea through 2030. The agreement covers all current and future uses of Yuviwel. BioMarin withdrew its ITC complaint and will dismiss related lawsuits. The settlement reinforces the value of BioMarin's CNP technology, used in its drug VOXZOGO. Analysts rate BMRN as a Buy with an $88.00 price target.
How this was made
The 30-second read
Why it matters
The agreement provides BioMarin with a new, predictable revenue source while removing litigation costs.
Market read
First‑report settlement introduces a royalty stream, modestly affecting BioMarin's valuation and offering a case study for IP settlements in biotech.
What to watch
Timing of royalty payments and potential future litigation risks could affect the actual cash flow.
Background
BioMarin and Ascendis resolved a long‑standing global patent dispute over CNP technology used in Yuviwel.
Ticker impact
BioMarin announced a settlement granting it royalties on Ascendis' Yuviwel sales, a new revenue stream through 2030.
Potential modest upside over the next months as royalty payments materialize, but limited immediate price move.
Royalty terms are clear and long‑term, yet the market reaction was slightly negative, suggesting traders may wait for payment confirmations.
Market effects
Sets a precedent for royalty settlements in rare‑disease biotech, may influence valuation of peers with similar IP disputes.
Impacts U.S., EU, Brazil and South Korea markets where Yuviwel is sold, but effect is limited to BioMarin.
Modest; primarily relevant to biotech investors tracking royalty‑based revenue streams.
Counterpoint
The settlement may signal underlying weakness in Ascendis' product, potentially limiting future royalty upside.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech receiving royalties.
- companyAscendis Pharma
Developer of Yuviwel, paying royalties.
